Literature DB >> 30753551

Advocating for Patients With Inflammatory Bowel Disease: How to Navigate the Prior Authorization Process.

Shubha Bhat1, Toni Zahorian1, Regine Robert1, Francis A Farraye2.   

Abstract

In an effort to manage health care costs and avoid improper medication use, prior authorizations (PAs) have become a standard stipulation required by payers in the determination of medication coverage. For gastroenterologists managing patients, especially those with inflammatory bowel disease (IBD), the PA process is time-consuming and further complicated by 2 additional factors: step therapy requirements and failure of payers to recognize updated IBD treatment pathways. These factors often lead to PA denials and cause treatment delays, which in turn can lead to disease progression, ongoing patient suffering, and ultimately an increase in both direct and indirect total costs. In this manuscript, the PA process, PA models, tips and available resources to navigate the PA process, and future advocacy efforts are discussed with the intent to help gastroenterology practices optimize PA outcomes and improve the care provided to patients with IBD and other gastrointestinal disorders.
© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; inflammatory bowel disease; prior authorization; step therapy; ulcerative colitis

Mesh:

Year:  2019        PMID: 30753551     DOI: 10.1093/ibd/izz013

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  2 in total

Review 1.  Evolving Role and Future Directions of Natural Language Processing in Gastroenterology.

Authors:  Fredy Nehme; Keith Feldman
Journal:  Dig Dis Sci       Date:  2020-02-27       Impact factor: 3.199

2.  Roles of Clinical Pharmacists in Caring for Patients With Inflammatory Bowel Disease During COVID-19.

Authors:  Shubha Bhat; Francis A Farraye; Alan Moss
Journal:  Gastroenterology       Date:  2020-05-18       Impact factor: 22.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.